ti.\*:("Pursuing therapeutic targets")
Results 1 to 14 of 14
Selection :
Pursuing therapeutic targetsVON HOFF, Daniel D; GRAY, Phillip J; DRAGOVICH, Tomislav et al.Seminars in oncology. 2006, Vol 33, Num 4, issn 0093-7754, 156 p.Serial Issue
Targeting HER2 epitopesSUMANTA KUMAR PAL; PEGRAM, Mark.Seminars in oncology. 2006, Vol 33, Num 4, pp 386-391, issn 0093-7754, 6 p.Article
Epidermal growth factor receptor targeting in cancerMENDELSOHN, John; BASELGA, Jose.Seminars in oncology. 2006, Vol 33, Num 4, pp 369-385, issn 0093-7754, 17 p.Article
Novel agents that target tublin and related elementsROWINSKY, Eric K; CALVO, Emiliano.Seminars in oncology. 2006, Vol 33, Num 4, pp 421-435, issn 0093-7754, 15 p.Article
Targeting the Bcl-2 family in cancer therapyPAPADOPOULOS, Kyriakos.Seminars in oncology. 2006, Vol 33, Num 4, pp 449-456, issn 0093-7754, 8 p.Article
New paradigms in anticancer therapy : Targeting multiple signaling pathways with kinase inhibitorsFAIVRE, Sandrine; DJELLOUL, Siham; RAYMOND, Eric et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 407-420, issn 0093-7754, 14 p.Article
Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agentsHONG WANG; HAIYONG HAN; MOUSSES, Spyro et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 513-520, issn 0093-7754, 8 p.Article
Role of raf kinase in cancer : Therapeutic potential of targeting the raf/MEK/ERK signal transduction pathwayGOLLOB, Jared A; WILHELM, Scott; CARTER, Chris et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 392-406, issn 0093-7754, 15 p.Article
Heat shock protein 90 : A unique chemotherapeutic targetCULLINAN, Sara B; WHITESELL, Luke.Seminars in oncology. 2006, Vol 33, Num 4, pp 457-465, issn 0093-7754, 9 p.Article
Tubulin-associated drug targets : Aurora kinases, polo-like kinases, and othersWARNER, Steven L; GRAY, Phillip J; VON HOFF, Daniel D et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 436-448, issn 0093-7754, 13 p.Article
The hypoxic inducible stress response as a target for cancer drug discoveryWELSH, Sarah J; MEI YEE KOH; POWIS, Garth et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 486-497, issn 0093-7754, 12 p.Article
Preclinical and clinical development of novel agents that target the protein kinase C familySEROVA, Maria; GHOUL, Aïda; BENHADJI, Karim A et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 466-478, issn 0093-7754, 13 p.Article
Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acidHUANG, Ru Chih C; CHIH CHUAN CHANG; MOLD, David et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 479-485, issn 0093-7754, 7 p.Article
Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer elementHURLEY, Laurence H; VON HOFF, Daniel D; SIDDIQUI-JAIN, Adam et al.Seminars in oncology. 2006, Vol 33, Num 4, pp 498-512, issn 0093-7754, 15 p.Article